Regularly eating fiber increases GLP-1 secretion due to the short-chain fatty acids produced in the microbiome
Current as of 6/18/26 Are there any clinical criteria for approval (e.g., BMI level, sustained weight min/max, step therapy such as a weight loss management program)
Decisions should be based on the patients metabolic health, cardiovascular risk, weight history, medications, family history, and overall clinical picture
Semaglutides ability to help maintain appetite suppression over the long term without significant side effects makes it an ideal option for individuals seeking lasting weight loss results
For many people, semaglutide helps create a sustainable calorie deficit without the constant hunger that often causes traditional diets to fail
Examples of licensed GLP-1 receptor agonists available in the UK include semaglutide (Ozempic for diabetes